Taxus Cardium Pharmaceuticals Group Inc  

(Public, OTCMKTS:CRXM)   Watch this stock  
Find more results for NYSEAMEX:CXM
0.520
0.000 (0.00%)
Jul 28 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.45 - 1.35
Open     -
Vol / Avg. 0.00/45,354.00
Mkt cap 6.23M
P/E     -
Div/yield     -
EPS -0.90
Shares 11.98M
Beta 2.84
Inst. own 7%
Aug 14, 2014
Q2 2014 Taxus Cardium Pharmaceuticals Group Inc Earnings Release - 9:30AM EDT - Add to calendar
Jun 22, 2014
Taxus Cardium Pharmaceuticals Group Inc at Biotechnology Industry Organization (BIO) International Convention
May 29, 2014
Taxus Cardium Pharmaceuticals Group Inc at Marcum MicroCap Conference
May 15, 2014
Q1 2014 Cardium Therapeutics Earnings Release
  

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -6324.91%
Operating margin - -6324.40%
EBITD margin - -6052.93%
Return on average assets -200.52% -130.38%
Return on average equity -608.83% -193.69%
Employees 11 -
CDP Score - -

Address

SUITE 250, 11750 SORRENTO VALLEY ROAD
SAN DIEGO, CA 92121
United States - Map
+1-858-4361000 (Phone)
+1-302-6365454 (Fax)

Website links

Description

Taxus Cardium Pharmaceuticals Group Inc, formerly Cardium Therapeutics, Inc., is a development-stage company. It�s business is focused on the acquisition and strategic development of product opportunities or businesses having the potential to address unmet medical needs. With additional products and distribution channels, the Company plans to develop MedPodium into a portfolio of science-based, easy to use medicinals, neurologics, metabolics, nutraceuticals and aesthetics intended to promote and manage personal health. On December 31, 2011, the Company acquires 15% ownership interest in SourceOne Global Partners, LLC. In October 2012, its MedPodium operating unit acquired the assets, business and product portfolio of To Go Brands.

Officers and directors

Christopher J. Reinhard Chairman of the Board, President, Chief Executive Officer, Treasurer
Age: 59
Dennis M. Mulroy CPA Chief Financial Officer
Age: 58
Tyler M. Dylan-Hyde J.D., Ph.D. Executive Vice President, Chief Business Officer, General Counsel, Secretary, Director
Age: 51
Gabor M. Rubanyi M.D., Ph.D. Chief Scientific Officer
Age: 66
Edward W. Gabrielson M.D. Independent Director
Age: 60
Murray H. Hutchison Independent Director
Age: 75
Andrew M. Leitch Independent Director
Age: 70
Gerald J. Lewis Independent Director
Age: 79
Lon E. Otremba Independent Director
Age: 56